San Francisco, CACIK 14427564 filings on record
Reported 13F value by quarter
Portfolio value trend — upgrade to see history
UpgradeLargest positions by weight
76 positions · Q4 2025
| # | Security | Shares | Value | % Port. | Δ Shares | Activity |
|---|---|---|---|---|---|---|
| 1 | Tenet Healthcare Corp | 397.8K | $79.04M | 8.1% | −63.9K | Reduced |
| 2 | Eli Lilly & Co | 68.3K | $73.39M | 7.5% | −156.8K | Reduced |
| 3 | Axsome Therapeutics Inc | 251.6K | $45.95M | 4.7% | −278.8K | Reduced |
| 4 | Penumbra Inc |
| 145.2K |
| $45.14M |
| 4.6% |
| −49.9K |
| Reduced |
| 5 | Ascendis Pharma A/S | 177.7K | $37.89M | 3.9% | +32.4K | Added |
| 6 | United Therapeutics Corp Del | 67.7K | $33.01M | 3.4% | −27.9K | Reduced |
| 7 | Centene Corp Del | 725.4K | $29.85M | 3.1% | +151.1K | Added |
| 8 | Bridgebio Pharma Inc | 306.5K | $23.44M | 2.4% | −20.7K | Reduced |
| 9 | Adma Biologics Inc | 1.27M | $23.18M | 2.4% | +89.9K | Added |
| 10 | Neurocrine Biosciences Inc | 163.2K | $23.15M | 2.4% | +106.0K | Added |
See this fund's complete portfolio, full position changes, and activity history.
Unlock full portfolio